Janus Henderson Global Life Sciences A (JFNAX)
58.99
+0.80 (+1.37%)
USD |
May 20 2022
Returns Chart
Key Stats
Customize
| Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
|---|---|---|---|
| 0.97% | 4.266B | 1.29% | 32.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
| -359.03M | -7.39% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks long-term growth of capital. The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio manager believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | JNGLX |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Janus Henderson |
| Prospectus Benchmark Index | |
| MSCI World/Health Care NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Andrew Acker | 15.01 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
87
-359.03M
-3.360B
Category Low
9.492B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of April 30, 2022
Performance Versus Category
As of May 20, 2022. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of May 20, 2022.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| UnitedHealth Group Inc | 5.87% | 485.73 | 1.50% |
|
AstraZeneca PLC
|
4.50% | -- | -- |
| AbbVie Inc | 3.87% | 151.01 | -0.47% |
|
Roche Holding AG
|
2.89% | -- | -- |
| Thermo Fisher Scientific Inc | 2.70% | 555.15 | 0.80% |
| Abbott Laboratories | 2.53% | 113.24 | 0.71% |
| Eli Lilly and Co | 2.52% | 298.85 | 4.39% |
| Bristol-Myers Squibb Co | 2.41% | 76.19 | 0.30% |
| Boston Scientific Corp | 2.38% | 39.22 | -0.68% |
| Danaher Corp | 2.35% | 251.80 | 1.00% |
Basic Info
| Investment Strategy | |
| The investment seeks long-term growth of capital. The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio manager believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | JNGLX |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Janus Henderson |
| Prospectus Benchmark Index | |
| MSCI World/Health Care NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Andrew Acker | 15.01 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (5-20-22) | 1.29% |
| 30-Day SEC Yield (8-31-17) | Upgrade |
| 7-Day SEC Yield (12-18-12) | Upgrade |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 25.40 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of March 31, 2022
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 7/6/2009 |
| Last Annual Report Date | 9/30/2021 |
| Last Prospectus Date | 1/28/2022 |
| Share Classes | |
| JAGLX | Other |
| JFNCX | C |
| JFNIX | Inst |
| JFNNX | N |
| JFNSX | S |
| JNGLX | D |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |